GSK
GSK agrees to buy Chimagen cancer program in deal worth up to $750 million
GSK agreed to acquire global rights to a Chimagen multiple myeloma program in a deal with an undisclosed upfront fee and contingent payments totaling up to $750 million.
GSK agreed to acquire global rights to a Chimagen multiple myeloma program in a deal with an undisclosed upfront fee and contingent payments totaling up to $750 million.
